Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
This study evaluates the safety of APN1125 for people with schizophrenia.
Understand this study
What is this study about?
This study evaluates the safety of APN1125 for people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 45 years. Other eligibility criteria apply.
- Listed locations
- Long BeachSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Suspended
- Enrollment listed in the registry
- 30
- Sponsor
- CoMentis
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02724917
- Official title
Show the full official title
A Phase 1b/2a, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
Recruitment & locations
Long Beach
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety of APN1125 for people with schizophrenia.
Who is behind this study?
The study sponsor is CoMentis.
Does this study involve medication?
Yes. The study involves medication, including APN1125 and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 45 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as suspended.
